Rocket Lab Stock Is Down 14%. Is It Finally Time to Buy?

Rocket Lab remains the second-most-used U.S. launch company and is gaining traction in both launch services and space systems, with backlog at $1.85 billion. A January fuel-tank rupture delayed Neutron to late 2026, a near-term headwind, but new wins including a $190 million hypersonic test-flight contract and additional Electron launches for iQPS support longer-term growth. Analysts still project revenue of $870 million this year and $1.2 billion in 2027, suggesting improving fundamentals despite the delay.

Analysis

The market is still pricing Rocket Lab as a binary launch story, but the more durable value creation is in the systems layer and in defense demand smoothing. A delayed Neutron only defers the re-rating from medium-lift optionality; it does not impair the current revenue engine, which is increasingly anchored by higher-margin hardware, subsystems, and integration services. That mix shift matters because it reduces dependence on the cadence of a single rocket program and makes earnings less lumpy than the headline launch narrative suggests.

Second-order winners are likely in the supply chain and adjacent defense names that benefit from hypersonic and national-security spending without carrying full launch execution risk. The hypersonic test-flight contract is more important as a customer-validation event than as near-term revenue: it signals Rocket Lab is becoming an authorized defense platform, which can shorten future procurement cycles and improve win rates for follow-on work. Competitors with pure-play launch exposure may lag if investors start favoring mixed hardware-defense business models with faster cash conversion.

The main risk is not just another technical delay; it is timeline drift that pushes the Neutron catalyst beyond the next 2-3 reporting cycles and forces the stock back into a “story stock” multiple regime. If that happens, the shares can de-rate even while fundamentals improve, because the market tends to reward visible launch milestones over backlog quality. A second risk is customer concentration: if a few large missions slip, near-term growth expectations can overshoot reality despite a healthy backlog.

The consensus appears to underweight how much of the upside is already financed by the existing book of business. The better debate is whether Neutron is incremental upside or merely a timing option on margin expansion; if the former, the current pullback may be attractive, but if the market continues to pay for visible launch execution, patience is required. This is a classic case where operational execution risk is higher than business quality risk.

Key Decisions for Investors

• Go long RKLB on weakness with a 6-12 month horizon; best risk/reward is a staged entry, since the downside is driven by another Neutron delay but the upside comes from multiple expansion if launch milestones land on schedule.
• For more convex exposure, buy RKLB call spreads expiring after the next expected Neutron catalyst window; this caps premium burn if the program slips again while preserving upside on a clean execution print.
• Pair trade: long RKLB / short a pure-play launch peer basket if you want to express the thesis that mixed defense + systems revenue should outgrow pure launch franchises over the next 12-18 months.
• If already long, trim into any pre-launch rally and re-add on post-event weakness; execution-heavy names often overrun into catalysts and then reset sharply on timing misses.
• Favor defense-adjacent suppliers over launch beta for lower drawdown: look for names tied to hypersonics, avionics, or space components where incremental defense spend can flow through faster than launch vehicle commercialization.